British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. The company said Wednesday that it started looking into the conduct of "a small number of individuals" in December. It says the investigation is ongoing.
The FDA has approved a new injectable drug from GlaxoSmithKline plc for adults with Type 2...
The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to...
Mylan has announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GSK relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.
Agenus Inc. announced that GlaxoSmithKline’s MAGRIT i study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon ® adjuvant, did not meet its first or second co-primary endpoint.
New research suggests that a shot every one to three months may someday give an alternative to the daily pills that some people take now to cut their risk of getting HIV.
Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this year's Winter Olympics: They're providing information on drugs that once would have been considered proprietary trade secrets.
GlaxoSmithKline says fourth-quarter earnings nearly tripled and sales rose 5 percent, even as an ongoing investigation hurt business in China.
Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.
Ligand Pharmaceuticals announced that its drug Promacta has received "breakthrough" designation by U.S. regulators for a new use in patients with a rare form of anemia. Ligand and its partner GlaxoSmithKline already market the pill to treat chronic hepatitis C and a rare condition called chronic immune thrombocytopenic purpura, in which the body attacks its own platelets.
The FDA has approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage). In May 2013, the FDA approved both drugs as single agents to treat patients with unresectable or metastatic melanoma.
Santaris Pharma A/S has signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK gains access to Santaris' Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines.
The Food and Drug Administration has approved a new once-a-day inhaler from GlaxoSmithKline PLC that combines two drugs to treat lung disease.
Merck has announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.
GlaxoSmithKline says it will stop offering financial support to doctors and other health-care professionals to promote its products. The change comes months after GSK was hit by an ongoing investigation of alleged bribery by its employees in China and signals a major shift in the way the company operates.
The companies said patients who took Breo Ellipta had a bigger improvement in lung function than patients who took the drug Flonase, which contains one of Breo Ellipta's two main components.
Takeda Pharmaceutical has announced that Christophe Weber has been approved at the company's Board of Directors Meeting to become Chief Operating Officer (COO) and candidate as the next Chief Executive Officer (CEO). Mr. Weber will join Takeda to take the role of COO by April 2014.
A government study offers a new theory on why the whooping cough vaccine doesn't seem to be working as well as expected. The research suggests that while the vaccine may keep people from getting sick, it doesn't prevent them from spreading whooping cough — also known as pertussis — to others.
The Food and Drug Administration is lifting severe safety restrictions on the former blockbuster diabetes pill Avandia, citing recent data suggesting that the much-debated medication does not increase the risk of heart attack.
The U.S. government has for the first time approved an adjuvanted vaccine to protect against H5N1 bird flu. The vaccine was made by Quebec City-based ID Biomedical, a subsidiary of pharmaceutical giant GlaxoSmithKline.
Pfizer announced today that it has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study (Study 200344) in patients with advanced/metastatic melanoma.
GlaxoSmithKline says a potential heart disease treatment it acquired as part of a key 2012 company takeover fell short in the main measurement of a late-stage study. Darapladib failed to produce a statistically significant reduction in major cardiovascular events like heart attacks, strokes or death when added to a patient's standard of care.
Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc. Janssen has acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs.
The FDA has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection.
GlaxoSmithKline PLC and Dutch biotech Prosensa Holding N.V. said Friday a potential treatment for Duchenne muscular dystrophy failed in a late-stage study to produce a significant difference in patients taking the drug compared with those who had a fake version.
ChemoCentryx has announced that GlaxoSmithKline has returned to ChemoCentryx all rights to vercirnon (also known as Traficet-EN and CCX282), an inhibitor of the chemokine receptor known as CCR9, for all indications, including the treatment of inflammatory bowel disease.
GlaxoSmithKline says it has sold its line of Lucozade and Ribena drinks brands to Suntory of Japan as part of the British company's effort to focus on its core pharmaceutical and health-care businesses.
- Page 1